Stimulation by peptide histidine methionine (PHM) of adrenocorticotropin secretion in patients with Cushing's disease: a comparison with the effect of vasoactive intestinal peptide (VIP) and a study on the effect of combined administration of corticotropin-releasing hormone with PHM or VIP.

Watanobe H, Tamura T

The Journal of clinical endocrinology and metabolism1 Jun 1994Cited by 6 (Europe PMC)

PMID8200939DOI10.1210/jcem.78.6.8200939PepBankPUB-08200939

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

5 results from studies that gave the peptide. 5 results from people.

01HumanNon-randomized trialEfficacy outcome
In 12 women with Cushing's disease, 5 (42%) responded to VIP with significant increases in both ACTH and cortisol.
In plain wordsIn women with Cushing's disease, VIP raised ACTH and cortisol in about four in ten patients.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseACTH and cortisol responders to VIP in Cushing's disease
Study
n = 12
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
100 micrograms · intravenous bolusAs given in this study (human).
Measurements
Responders
5 patients
VIP, Cushing's disease
Responders
42%
VIP, Cushing's disease
Source sentences
Summary
Of the patients with Cushing's disease, 9 (75%) were responsive to hCRH, 5 (42%) were to VIP, and 3 (25%) were to PHM, showing significant increases in both ACTH and cortisol.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
Report a problemFND-0820093903
02HumanNon-randomized trialMechanism
In women with Cushing's disease, all 5 VIP responders were also responsive to hCRH.
In plain wordsIn women with Cushing's disease, everyone whose ACTH rose after VIP also responded to CRH.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableOverlap of VIP and hCRH responders in Cushing's disease
Study
n = 12
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
100 micrograms · intravenous bolusAs given in this study (human).
Source sentences
Summary
All the 3 PHM responders were also responsive to VIP, and all the 5 VIP responders were also responsive to hCRH.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
Report a problemFND-0820093904
03HumanNon-randomized trialEfficacy outcome
In 8 normal women, VIP had no effect on ACTH secretion.
In plain wordsIn healthy women, VIP did not change ACTH levels.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeACTH response to VIP in normal women
Study
n = 8
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
100 micrograms · intravenous bolusAs given in this study (human).
Source sentences
Summary
In all normal subjects, hCRH induced significant rises in ACTH (> 50% above the basal) and cortisol (> 20% above the basal), but PHM and VIP were without effect.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
Report a problemFND-0820093901
04HumanNon-randomized trialEfficacy outcome
In 8 normal women, VIP had no effect on cortisol secretion.
In plain wordsIn healthy women, VIP did not change cortisol levels.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeCortisol response to VIP in normal women
Study
n = 8
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
100 micrograms · intravenous bolusAs given in this study (human).
Source sentences
Summary
In all normal subjects, hCRH induced significant rises in ACTH (> 50% above the basal) and cortisol (> 20% above the basal), but PHM and VIP were without effect.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
Report a problemFND-0820093902
05HumanNon-randomized trialEfficacy outcome
In 8 normal women, hormonal responses after hCRH plus VIP were statistically indistinguishable from those after hCRH alone.
In plain wordsIn healthy women, adding VIP to CRH did not change the hormone response compared with CRH alone.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
No significant changeACTH and cortisol response to hCRH plus VIP versus hCRH alone in normal women
Study
n = 8
Comparator
hCRH alone
Outcome group
Stress hormones · Endocrine and hormones
Studied dose
100 micrograms · intravenous bolusAs given in this study (human).
Source sentences
Summary
In this group, hormonal responses after hCRH plus PHM and hCRH plus VIP were statistically indistinguishable from those after hCRH alone.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
Report a problemFND-0820093905

Studies that did not test the peptide alone2

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

06HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialEfficacy outcome
In patients with Cushing's disease, coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
In plain wordsIn people with Cushing's disease, giving CRH together with PHM or VIP gave additive rises in ACTH and cortisol.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseACTH and cortisol response to hCRH plus VIP in Cushing's disease
Study
n = 12
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
In addition, in the patients with Cushing's disease the coadministration of hCRH with PHM or VIP produced additive increases in both ACTH and cortisol.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0820093906
07HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism
In patients with Cushing's disease, pooled responders to VIP and PHM had higher ACTH and cortisol responses to hCRH than nonresponders.
In plain wordsIn people with Cushing's disease, those who reacted to VIP or PHM also reacted more strongly to CRH than those who did not.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasehCRH response in VIP and PHM responders versus nonresponders in Cushing's disease
Study
n: not reported in source
Comparator
Nonresponders
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
Interestingly, the responders to VIP and PHM had higher ACTH and cortisol responses to hCRH compared with the nonresponders.
2 context sentences(design, population, supporting numbers)
Summary · context
The effect of peptide histidine methionine (PHM) on ACTH and cortisol secretion was examined in 12 female patients with Cushing's disease and 8 normal women.
Summary · context
Each peptide was given as an i.v. bolus in a dose of 100 micrograms, and plasma levels of ACTH and cortisol were measured before and at intervals up to 120 min after the injection.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-0820093907

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.